At every research site, the Principal Investigator (PI) is the individual ultimately accountable for how a study is conducted.
The PI leads the study team, oversees participant safety, and ensures that every procedure, record, and decision follows the approved protocol and regulatory standards.
The success of the study at each site largely depends on how effectively the investigator and their team execute it.
A well-prepared investigator can support efficient study start-up, maintain regulatory compliance, and deliver reliable clinical data throughout the trial.
What ICH GCP Requires of a Principal Investigator
The Good Clinical Practice guideline (ICH E6) defines the investigator as the person responsible for conducting the clinical trial at a trial site. That definition carries a substantial set of obligations, which ICH E6 breaks down across several domains.
- Qualifications and training.
A PI must have the appropriate medical or scientific qualifications, documented expertise in the therapeutic area being studied, and current training in Good Clinical Practice. - Protocol compliance.
The PI is responsible for conducting the trial in accordance with the approved protocol and the signed investigator agreement. Any deviations from the protocol must be documented and reported to the sponsor and ethics committee. - Informed consent.
The PI must ensure that written informed consent is obtained from every participant before enrolment and that the process follows both ICH GCP standards and the ethical principles of the Declaration of Helsinki. - Medical care and safety.
A qualified physician must be responsible for all medical decisions related to participants in a clinical trial. Serious adverse events must be reported to the sponsor promptly and documented accurately.
Although research staff may assist with safety reporting, the PI remains responsible for ensuring that all safety obligations are fulfilled. Participant welfare must always take precedence over scientific objectives. - Records and documentation.
Clinical trials generate a large volume of documentation that provides evidence that the study was conducted in accordance with regulatory requirements.
The PI is responsible for maintaining all essential trial documents throughout the study. The Source documents must be accurate, complete, legible, and traceable to the participant and the date of creation. - Progress reporting.
The PI must submit annual written summaries to the ethics committee and promptly notify both the sponsor and the ethics committee of any developments that significantly affect the conduct of the trial or increase risk to participants.
The Role of a Principal Investigator
The day-to-day responsibilities of a PI differ depending on the type of research being conducted.
Sponsor-Led Trials
In sponsor-led trials, the protocol, funding, and study drug or device come from the sponsoring pharmaceutical company or device manufacturer.
The PI activates the site, manages the team, ensures compliance, and is accountable for how the study is executed at their site.
They may also contribute to the study design through advisory roles or feasibility input, but the intellectual property and regulatory ownership belong to the sponsor.
Investigator-Initiated Trials
In investigator-led trials, the PI both designs and leads the study. They develop the research question, write the protocol, assemble and lead the team, navigate ethics and regulatory approvals independently, and secure funding through grant applications.
Grant writing becomes an essential competency in this pathway, as the ability to secure funding determines whether the study can proceed
How Sponsors Evaluate Principal Investigators During Site Selection
One of the key indicators of a PI’s readiness is how they perform during site activation, the period when a sponsor or CRO is deciding whether to select and open a site for a multi-centre trial.
Sponsors assess sites through feasibility questionnaires, pre-study visits, and review of historical performance data. The key criteria evaluated include:
The PI’s qualifications and track record. Sponsors look for prior GCP-compliant trial experience in the relevant therapeutic area, documented inspection readiness, and a record of publication or regulatory submissions that demonstrate scientific engagement with the field.
Team composition and stability. The PI does not execute a trial alone. The sub-investigators, the study coordinator, and the broader team are evaluated. A capable, stable team that has worked together across multiple studies is a significant indicator of site reliability.
Enrollment history. Has this site consistently met its enrollment targets in previous studies? Enrollment failure is one of the most cited causes of trial delays and budget overruns.
A PI who has delivered on recruitment commitments builds a track record that sponsors return to, and a site that has repeatedly over-promised and under-delivered will find it difficult to be selected for future studies.
Protocol comprehension. A PI who has studied the protocol carefully can identify potential recruitment challenges, flag feasibility concerns, and propose practical solutions. This level of engagement signals to a sponsor that the site has genuinely invested in understanding what the study requires.
Regulatory compliance history. Sponsors and CROs review previous audit and inspection findings. A pattern of significant protocol deviations, adverse event reporting failures, or GCP findings from past studies is a disqualifying factor at many sponsors.
What Separates Good PIs from Great Ones
Meeting regulatory requirements is only the baseline for the PI role.
- Outstanding investigators distinguish themselves through leadership, communication, and scientific engagement.
- They prioritise participant welfare, invest in developing strong research teams, and maintain transparent communication with sponsors and CROs when operational challenges arise.
- In addition, they also remain actively engaged in their therapeutic areas through publications, conferences, and collaboration with research networks.
- Most importantly, they provide realistic recruitment projections and operational assessments, recognising that reliability is more valuable to sponsors than overly optimistic promises.
The Pathway to Becoming a Principal Investigator
Most Principal Investigator develop their research leadership gradually through hands-on experience in clinical trials.
For many clinicians and researchers, the journey typically begins by joining an active study team as a Sub-Investigator, Study Coordinator, or Clinical Research Associate at the site level. provide practical exposure to how trials operate on a day-to-day basis.
Through participation in active studies, gain experience with:
- Regulatory and ethics committee submissions.
- Protocol implementation and study procedures
- Participant recruitment and retention strategies
- Adverse event reporting and safety monitoring
- Monitoring visits and sponsor communication
- Data documentation and query resolution
For clinicians, this can involve contacting the research office at a teaching hospital or an active investigative site and asking to be listed as a sub-investigator on a current study. This is the fastest way to develop working familiarity with how a trial operates at the site level.
Clinical research across Nigeria and West Africa is expanding as global sponsors seek greater population diversity and new research partnerships.
Investigators who combine strong clinical expertise, regulatory knowledge, and operational readiness will play a central role in shaping the future of clinical research across the region.
At UCTSS, we work closely with investigators, sites, sponsors, and research teams to support the delivery of ethical, compliant, and high-quality clinical trials in Nigeria and West Africa.
Learn more about our services: info@unitedclinicals.com
Add a Comment